Skip to main content
SpringerLink
Log in

C4 Drugs for the treatment of airway disease

  • Chapter
  • First Online:
Principles of Immunopharmacology

  • 1911 Accesses

Abstract

Both asthma and chronic obstructive pulmonary disease (COPD) are characterized by airflow obstruction and chronic inflammation of the airways, but there are important differences in inflammatory mechanisms and response to therapy between these diseases [1, 2]. This chapter discusses the pharmacology of the drugs used in the treatment of obstructive airways diseases. These drugs include bronchodilators, which act mainly by reversing airway smooth muscle contraction and anti-inflammatory drugs, which in asthma suppress the inflammatory response in the airways. The most effective anti-inflammatory treatment for asthma is corticosteroids, which are covered in chapter C13. In COPD, no effective anti-inflammatory drugs are available, but several new classes of drug are now in development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest 2000; 117: 10S–14S

    PubMed  CAS  Google Scholar 

  2. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Immunol Rev 2008; 8: 183–192

    CAS  Google Scholar 

  3. Kips JC, Pauwels RA. Long-acting inhaled β2-agonist therapy in asthma. Am J Respir Crit Care Med 2001; 164: 923–932

    PubMed  CAS  Google Scholar 

  4. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 2008; 155: 291–299

    PubMed  CAS  Google Scholar 

  5. Holz GG, Kang G, Harbeck M, Roe MW, Chepurny OG. Cell physiology of cAMP sensor Epac. J Physiol 2006; 577: 5–15

    PubMed  CAS  Google Scholar 

  6. Nightingale JA, Rogers DF, Barnes PJ. Comparison of the effects of salmeterol and formoterol in patients with severe asthma. Chest 2002; 121: 1401–1406

    PubMed  CAS  Google Scholar 

  7. Tattersfield AE, Lofdahl CG, Postma DS, Eivindson A, Schreurs AG, Rasidakis A, Ekstrom T. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001; 357: 257–261

    PubMed  CAS  Google Scholar 

  8. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM. Long-acting β-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3: CD001104

    Google Scholar 

  9. Barnes PJ. Scientific rationale for combination inhalers with a long-acting β2-agonists and corticosteroids. Eur Respir J 2002; 19: 182–191

    PubMed  CAS  Google Scholar 

  10. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo U. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised, controlled double-blind study. Lancet 2006; 368: 744–753

    PubMed  CAS  Google Scholar 

  11. Lotvall J, Palmqvist M, Arvidsson P, Maloney A, Ventresca GP, Ward J. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001; 108: 726–731

    PubMed  CAS  Google Scholar 

  12. Barnes PJ. Treatment with (R)-albuterol has no advantage over racemic albuterol. Am J Respir Crit Care Med 2006; 174: 969–972

    PubMed  CAS  Google Scholar 

  13. Madaan A. Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc) 2009; 45: 3–9

    Google Scholar 

  14. Hawkins GA, Weiss ST, Bleecker ER. Clinical consequences of ADRbeta2 polymorphisms. Pharmacogenomics 2008; 9: 349–358

    PubMed  CAS  Google Scholar 

  15. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370: 2118–2125

    PubMed  CAS  Google Scholar 

  16. McGraw DW, Liggett SB. Heterogeneity in beta-adrenergic receptor kinase expression in the lung accounts for cell-specific desensitization of the beta2-adrenergic receptor. J Biol Chem 1997; 272: 7338–7344

    PubMed  CAS  Google Scholar 

  17. Mak JCW, Nishikawa M, Shirasaki H, Miyayasu K, Barnes PJ. Protective effects of a glucocorticoid on downregulation of pulmonary β2-adrenergic receptors in vivo. J Clin Invest 1995; 96: 99–106

    PubMed  CAS  Google Scholar 

  18. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbcek B, Cockroft D, Boivin J-F, McNutt M, Buist AS, Rebuck AS. The use of β-agonists and the rate of death and neardeath from asthma. N Engl J Med 1992; 326: 503–506

    Google Scholar 

  19. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Lowdose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332–336

    PubMed  CAS  Google Scholar 

  20. Sears MR, Taylor DR, Print CG, Lake DG, Li Q, Flannery EM, Yates DM, Lucas MK, Herbison GP. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391–1396

    PubMed  CAS  Google Scholar 

  21. Dennis SM, Sharp SJ, Vickers MR, Frost CD, Crompton GK, Barnes PJ, Lee TH. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Lancet 2000; 355: 1675–1679

    PubMed  CAS  Google Scholar 

  22. Mcivor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158: 924–930

    PubMed  CAS  Google Scholar 

  23. McGraw DW, Almoosa KF, Paul RJ, Kobilka BK, Liggett SB. Antithetic regulation by β-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway β-agonist paradox. J Clin Invest 2003; 112: 619–626

    PubMed  CAS  Google Scholar 

  24. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15–26

    PubMed  CAS  Google Scholar 

  25. Jaeschke R, O’Byrne PM, Mejza F, Nair P, Lesniak W, Brozek J, Thabane L, Cheng J, Schunemann HJ, Sears MR, Guyatt G. The safety of long-acting β-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med 2008; 178: 1009–1016

    PubMed  CAS  Google Scholar 

  26. Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010; 65: 39–43

    PubMed  CAS  Google Scholar 

  27. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789

    PubMed  CAS  Google Scholar 

  28. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest 2008; 133: 1079–1087

    PubMed  CAS  Google Scholar 

  29. Barnes PJ. Theophylline: new perspectives on an old drug. Am J Respir Crit Care Med 2003; 167: 813–818

    PubMed  Google Scholar 

  30. Dini FL, Cogo R. Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects. Curr Med Res Opin 2001; 16: 258–268

    PubMed  CAS  Google Scholar 

  31. Lim S, Tomita K, Carramori G, Jatakanon A, Oliver B, Keller A, Adcock I, Chung KF, Barnes PJ. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med 2001; 164: 273–276

    PubMed  CAS  Google Scholar 

  32. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by the asthma: demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995; 151: 1907–1914

    PubMed  CAS  Google Scholar 

  33. Culpitt SV, de Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in COPD. Am J Respir Crit Care Med 2002; 165: 1371–1376

    PubMed  Google Scholar 

  34. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002; 99: 8921–8926

    PubMed  CAS  Google Scholar 

  35. Wilson CN. Adenosine receptors and asthma in humans. Br J Pharmacol 2008; 155: 475–486

    PubMed  CAS  Google Scholar 

  36. Oliver B, Tomita K, Keller A, Caramori G, Adcock I, Chung KF, Barnes PJ, Lim S. Low-dose theophylline does not exert its anti-inflammatory effects in mild asthma through upregulation of interleukin-10 in alveolar macrophages. Allergy 2001; 56: 1087–1090

    PubMed  CAS  Google Scholar 

  37. Ichiyama T, Hasegawa S, Matsubara T, Hayashi T, Furukawa S. Theophylline inhibits NF-κB activation and IκBa degradation in human pulmonary epithelial cells. Naunyn Schmiedebergs Arch Pharmacol 2001; 364: 558–561

    PubMed  CAS  Google Scholar 

  38. Chung IY, Nam-Kung EK, Lee NM, Chang HS, Kim DJ, Kim YH, Park CS. The downregulation of bcl-2 expression is necessary for theophylline-induced apoptosis of eosinophil. Cell Immunol 2000; 203: 95–102

    PubMed  CAS  Google Scholar 

  39. Yasui K, Agematsu K, Shinozaki K, Hokibara S, Nagumo H, Nakazawa T, Komiyama A. Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism. J Leukoc Biol 2000; 67: 529–535

    PubMed  CAS  Google Scholar 

  40. Ohta K, Yamashita N. Apoptosis of eosinophils and lymphocytes in allergic inflammation. J Allergy Clin Immunol 1999; 104: 14–21

    PubMed  CAS  Google Scholar 

  41. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004; 200: 689–695

    PubMed  CAS  Google Scholar 

  42. Marwick JA, Caramori G, Stevenson CC, Casolari P, Jazrawi E, Barnes PJ, Ito K, Adcock IM, Kirkham PA, Papi A. Inhibition of PI3Kd restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med. 2009; 179: 542–548

    PubMed  CAS  Google Scholar 

  43. To M, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, Elliot M, Hogg JC, Adcock IM, Barnes PJ. Targeting phosphoinositide- 3-kinase-d with theophylline reverses corti costeroid insensitivity in COPD. Am J Respir Crit Care Med 2010; 182: 897–904

    PubMed  CAS  Google Scholar 

  44. Zhang ZY, Kaminsky LS. Characterization of human cytochromes P450 involved in theophylline 8–hydroxylation. Biochem Pharmacol 1995; 50: 205–211

    PubMed  CAS  Google Scholar 

  45. Parameswaran K, Belda J, Rowe BH. Addition of intravenous aminophylline to beta2-agonists in adults with acute asthma. Cochrane Database Syst Rev 2000: CD002742

    Google Scholar 

  46. Rivington RN, Boulet LP, Cote J, Kreisman H, Small DI, Alexander M, Day A, Harsanyi Z, Darke AC. Efficacy of slow-release theophylline, inhaled salbutamol and their combination in asthmatic patients on high-dose inhaled steroids. Am J Respir Crit Care Med 1995; 151: 325–332

    PubMed  CAS  Google Scholar 

  47. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O’Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337: 1412–1418

    PubMed  CAS  Google Scholar 

  48. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, Leichtl S, Rathgeb F, Keller A, Steinijans VW. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 1997; 10: 2754–2760

    PubMed  CAS  Google Scholar 

  49. Lim S, Jatakanon A, Gordon D, Macdonald C, Chung KF, Barnes PJ. Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax 2000; 55: 837–841

    PubMed  CAS  Google Scholar 

  50. Wilson AJ, Gibson PG, Coughlan J. Long acting betaagonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev 2000: CD001281

    Google Scholar 

  51. Shah L, Wilson AJ, Gibson PG, Coughlan J. Long acting beta-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev 2003: CD001281

    Google Scholar 

  52. Brenner MR, Berkowitz R, Marshall N, Strunk RC. Need for theophylline in severe steroid-requiring asthmatics. Clin Allergy 1988; 18: 143–150

    PubMed  CAS  Google Scholar 

  53. Seddon P, Bara A, Ducharme FM, Lasserson TJ. Oral xanthines as maintenance treatment for asthma in children. Cochrane Database Syst Rev 2006: CD002885

    Google Scholar 

  54. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, Fitzgerald M, Gibson P, Ohta K, O’Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 143–178

    PubMed  CAS  Google Scholar 

  55. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of COPD – 2006 Update. Am J Respir Crit Care Med. 2007; 176: 532–555

    PubMed  Google Scholar 

  56. Ram FS, Jones PW, Castro AA, De Brito JA, Atallah AN, Lacasse Y, Mazzini R, Goldstein R, Cendon S. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002: CD003902

    Google Scholar 

  57. Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. Br Med J 2003; 327: 643

    CAS  Google Scholar 

  58. Duffy N, Walker P, Diamantea F, Calverley PM, Davies L. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Thorax 2005; 60: 713–717

    PubMed  CAS  Google Scholar 

  59. Cosio BG, Iglesias A, Rios A, Noguera A, Sala E, Ito K, Barnes PJ, Agusti A. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of chronic obstructive pulmonary disease. Thorax 2009; 64: 424–429

    PubMed  CAS  Google Scholar 

  60. Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol 2008; 154: 1558–1571

    PubMed  CAS  Google Scholar 

  61. Bateman ED, Rennard S, Barnes PJ, Dicpinigaitis PV, Gosens R, Gross NJ, Nadel JA, Pfeifer M, Racke K, Rabe KF, Rubin BK, Welte T, Wessler I. Alternative mechanisms for tiotropium. Pulm Pharmacol Ther 2009; 22: 533–542

    PubMed  CAS  Google Scholar 

  62. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax 2006; 61: 854–862

    PubMed  CAS  Google Scholar 

  63. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–1554

    PubMed  CAS  Google Scholar 

  64. Hansel TT, Neighbour H, Erin EM, Tan AJ, Tennant RC, Maus JG, Barnes PJ. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 2005; 128: 1974–1979

    PubMed  CAS  Google Scholar 

  65. Cazzola M. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Curr Opin Investig Drugs 2009; 10: 482–490

    PubMed  CAS  Google Scholar 

  66. Tennant RC, Erin EM, Barnes PJ, Hansel TT. Long-acting β2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified? Curr Opin Pharmacol 2003; 3: 270–276

    PubMed  CAS  Google Scholar 

  67. Ray NC, Alcaraz L. Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review. Expert Opin Ther Pat 2009; 19: 1–12

    PubMed  CAS  Google Scholar 

  68. Mohammed S, Goodacre S. Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis. Emerg Med J 2007; 24: 823– 830

    PubMed  CAS  Google Scholar 

  69. Emelyanov A, Fedoseev G, Barnes PJ. Reduced intracellular magnesium concentrations in asthmatic subjects. Eur Respir J 1999; 13: 38–40

    PubMed  CAS  Google Scholar 

  70. Skorodin MS, Tenholder MF, Yetter B, Owen KA, Waller RF, Khandelwahl S, Maki K, Rohail T, D’Alfonso N. Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 1995; 155: 496–500

    PubMed  CAS  Google Scholar 

  71. Black JL, Armour CL, Johnson PRA, Alouan LA, Barnes PJ. The action of a potassium channel activator BRL 38227 (lemakalim) on human airway smooth muscle. Am Rev Respir Dis 1990; 142: 1384–1389

    PubMed  CAS  Google Scholar 

  72. Pelaia G, Gallelli L, Vatrella A, Grembiale RD, Maselli R, De Sarro GB, Marsico SA. Potential role of potassium channel openers in the treatment of asthma and chronic obstructive pulmonary disease. Life Sci 2002; 70: 977–990

    PubMed  CAS  Google Scholar 

  73. Angus RM, Mecallaum MJA, Hulks G, Thomson NC. Bronchodilator, cardiovascular and cyclic guanylyl monophosphate response to high dose infused atrial natriuretic peptide in asthma. Am Rev Respir Dis 1993; 147: 1122–1125

    PubMed  CAS  Google Scholar 

  74. Fluge T, Forssmann WG, Kunkel G, Schneider B, Mentz P, Forssmann K, Barnes PJ, Meyer M. Bronchodilation using combined urodilatin-albuterol administration in asthma: a randomized, double-blind, placebo-controlled trial. Eur J Med Res 1999; 4: 411–415

    PubMed  CAS  Google Scholar 

  75. Linden A, Hansson L, Andersson A, Palmqvist M, Arvidsson P, Lofdahl CG, Larsson P, Lotvall J. Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma. Thorax 2003; 58: 217–221

    PubMed  CAS  Google Scholar 

  76. Norris AA. Pharmacology of sodium cromoglycate. Clin Exp Allergy 1996; 26 Suppl 4: 5–7: 5–7

    Google Scholar 

  77. van der Wouden JC, Uijen JH, Bernsen RM, Tasche MJ, de Jongste JC, Ducharme F. Inhaled sodium cromogly cate for asthma in children. Cochrane Database Syst Rev 2008: CD002173

    Google Scholar 

  78. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998; 50: 515–596

    PubMed  CAS  Google Scholar 

  79. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharm Rev 2004; 56: 515–548

    PubMed  CAS  Google Scholar 

  80. van Ganse E, Kaufman L, Derde MP, Yernault JC, Delaunois L. Effcts of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J 1997; 10: 2216–2224

    PubMed  Google Scholar 

  81. Lordan JL, Holgate ST. H1–antihistamines in asthma. Clin Allergy Immunol 2002; 17: 221–248

    PubMed  CAS  Google Scholar 

  82. Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 1990; 40: 412–448

    Google Scholar 

  83. Peters-Golden M, Henderson WR, Jr. Leukotrienes. N Engl J Med 2007; 357: 1841–1854

    PubMed  CAS  Google Scholar 

  84. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111: 913–921

    PubMed  CAS  Google Scholar 

  85. Calhoun WJ. Anti-leukotrienes for asthma. Curr Opin Pharmacol 2001; 1: 230–234

    PubMed  CAS  Google Scholar 

  86. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. Br Med J 2003; 326: 621–624

    CAS  Google Scholar 

  87. Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006: CD003137

    Google Scholar 

  88. Robinson DS, Campbell DA, Barnes PJ. Addition of an anti-leukotriene to therapy in chronic severe asthma in a clinic setting: a double-blind, randomised, placebo- controlled study. Lancet 2001; 357: 2007–2011

    PubMed  CAS  Google Scholar 

  89. Dahlen SE, Malmstrom K, Nizankowska E, Dahlen B, Kuna P, Kowalski M, Lumry WR, Picado C, Stevenson DD, Bousquet J, Pauwels R, Holgate ST, Shahane A, Zhang J, Reiss TF, Szczeklik A. Improvement of aspirinintolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 9–14

    PubMed  Google Scholar 

  90. Coreno A, Skowronski M, Kotaru C, McFadden ER, Jr. Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma. J Allergy Clin Immunol 2000; 106: 500–506

    PubMed  CAS  Google Scholar 

  91. Nathan RA. Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. Ann Allergy Asthma Immunol 2003; 90: 182–190

    PubMed  CAS  Google Scholar 

  92. Minoguchi K, Kohno Y, Minoguchi H, Kihara N, Sano Y, Yasuhara H, Adachi M. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 2002; 121: 732–738

    PubMed  CAS  Google Scholar 

  93. O’Sullivan S, Akveld M, Burke CM, Poulter LW. Effect of the addition of montelukast to inhaled fluticasone propionate on airway inflammation. Am J Respir Crit Care Med 2003; 167: 745–750

    PubMed  Google Scholar 

  94. Gompertz S, Stockley RA. A randomized, placebocontrolled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 2002; 122: 289–294

    PubMed  CAS  Google Scholar 

  95. Nathani N, Little MA, Kunst H, Wilson D, Thickett DR. Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 2008; 63: 883– 888

    PubMed  CAS  Google Scholar 

  96. Tantisira KG, Drazen JM. Genetics and pharmacogenetics of the leukotriene pathway. J Allergy Clin Immunol 2009; 124: 422–427

    PubMed  CAS  Google Scholar 

  97. Back M. Functional characteristics of cysteinyl-leukotriene receptor subtypes. Life Sci 2002; 71: 611–622

    PubMed  CAS  Google Scholar 

  98. Hill SJ, Tattersfield AE. Corticosteroid sparing agents in asthma. Thorax 1995; 50: 577–582

    PubMed  CAS  Google Scholar 

  99. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000; 2: CD000391

    Google Scholar 

  100. Evans DJ, Cullinan P, Geddes DM. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001: CD002985

    Google Scholar 

  101. Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma (Cochrane Review). Cochrane Database Syst Rev 2001; 2: CD002993

    Google Scholar 

  102. Rolland JM, Gardner LM, O’Hehir RE. Allergen-related approaches to immunotherapy. Pharmacol Ther 2009; 121: 273–284

    PubMed  CAS  Google Scholar 

  103. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6: 761–771

    PubMed  CAS  Google Scholar 

  104. Broide DH. Immunomodulation of allergic disease. Annu Rev Med 2009; 60: 279–291

    PubMed  CAS  Google Scholar 

  105. Avila PC. Does anti-IgE therapy help in asthma? Efficacy and controversies. Annu Rev Med 2007; 58: 185–203

    PubMed  CAS  Google Scholar 

  106. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006: CD003559

    Google Scholar 

  107. Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab- associated anaphylaxis. J Allergy Clin Immunol 2007; 120: 1373–1377

    PubMed  CAS  Google Scholar 

  108. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008; 372: 1073–1087

    PubMed  CAS  Google Scholar 

  109. Barnes PJ. New drugs for asthma: is there any progress? Trends Pharmacol Sci 2010

    Google Scholar 

  110. Barnes PJ. Emerging pharmacotherapies for COPD. Chest 2008; 134: 1278–1286

    PubMed  CAS  Google Scholar 

  111. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006; 130: 65S-72S

    PubMed  Google Scholar 

  112. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005; 25: 1084–1106

    PubMed  CAS  Google Scholar 

  113. Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007; 6: 313–325

    PubMed  CAS  Google Scholar 

  114. Kirkham P, Rahman I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther 2006; 111: 476–494

    PubMed  CAS  Google Scholar 

  115. Hobbs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol 1999; 39: 191–220

    PubMed  CAS  Google Scholar 

  116. Hansel TT, Kharitonov SA, Donnelly LE, Erin EM, Currie MG, Moore WM, Manning PT, Recker DP, Barnes PJ. A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics. FASEB J 2003; 17: 1298–1300

    PubMed  CAS  Google Scholar 

  117. Singh D, Richards D, Knowles RG, Schwartz S, Woodcock A, Langley S, O’Connor BJ. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am J Respir Crit Care Med 2007; 176: 988–993

    PubMed  CAS  Google Scholar 

  118. Barnes PJ. Cytokine networks in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008; 118: 3546–3556

    PubMed  CAS  Google Scholar 

  119. Leckie MJ, ten Brincke A, Khan J, Diamant Z, O’Connor BJ, Walls CM, Mathur M, Cowley H, Chung KF, Djukanovic RJ, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response. Lancet 2000; 356: 2144–2148

    PubMed  CAS  Google Scholar 

  120. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, Barnes NC. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007; 176: 1062–1071

    PubMed  CAS  Google Scholar 

  121. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973–984

    PubMed  CAS  Google Scholar 

  122. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohoue JF, Watt R, Hung KL, Schlenker-Herceg R et al. The safety and efficacy of infliximab in moderateto- severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 926–934

    PubMed  CAS  Google Scholar 

  123. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlen SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P. A randomized, double-blind, placebo-controlled study of TNF-α blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179: 549–558

    PubMed  CAS  Google Scholar 

  124. Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 2008; 48: 171–197

    PubMed  CAS  Google Scholar 

  125. Donnelly LE, Barnes PJ. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006; 27: 546–553

    PubMed  CAS  Google Scholar 

  126. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase- 4 as a therapeutic target. Drug Discov Today 2005; 10: 1503–1519

    PubMed  CAS  Google Scholar 

  127. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695–703

    PubMed  CAS  Google Scholar 

  128. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066–1071

    PubMed  CAS  Google Scholar 

  129. Kishore N, Sommers C, Mathialagan S, Guzova J, Yao M, Hauser S, Huynh K, Bonar S, Mielke C, Albee L, Weier R, Graneto M, Hanau C, Perry T, Tripp CS. A selective IKK-2 inhibitor blocks NF-kappaB-dependent gene expression in IL-1beta stimulated synovial fibroblasts. J Biol Chem 2003; 277: 13840–13847

    Google Scholar 

  130. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17–26

    PubMed  CAS  Google Scholar 

  131. Delhase M, Li N, Karin M. Kinase regulation in inflammatory response. Nature 2000; 406: 367–368

    PubMed  CAS  Google Scholar 

  132. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007; 1773: 1358–1375

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Airways Disease, National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse St, London, SW3 6LY, UK

    Peter J. Barnes

Authors
  1. Peter J. Barnes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter J. Barnes .

Editor information

Editors and Affiliations

  1. Faculteit Farmacie, Rijksuniversiteit Utrecht, Utrecht, Netherlands

    F.P. Nijkamp

  2. Diseases "Dr. Fran Mihaljevic", Research & Clinical Immunology Unit, University Hospital for Infectious, Mirogojska cesta 8, Zagreb, 10000, Croatia

    Michael J. Parnham

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Birkhäuser Basel

About this chapter

Cite this chapter

Barnes, P.J. (2011). C4 Drugs for the treatment of airway disease. In: Nijkamp, F., Parnham, M. (eds) Principles of Immunopharmacology. Birkhäuser Basel. https://doi.org/10.1007/978-3-0346-0136-8_19

Download citation

Publish with us

Policies and ethics

Search

Navigation